Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — FY2022 Earnings Presentation
9 slides from Hls Therapeutics's earnings presentation, Mar 16, 2023
Slide 1: Q4 & F2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2022 Results Conference Call March 16, 2023 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Q4 & F2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2022 Results Conference Call March 16, 2023 TSX - HLS
Slide 4: Prescription momentum growing
Vascepa: Prescription momentum growing Weekly script data since launch 1800 Quebec New Rx: 1600 124% increase* 1400 Ontario New Rx: 1200 67% increase* Prescriptions 1000 (*Q4 2022 compared to Q4 2021) 800 Q4 600 400 3,300 physicians have prescribed Vascepa 200 92% increase* 0 (*as at Dec 31, 2022 co
Slide 5: Growth outpacing other cardiovascular therapies
Vascepa: growth outpacing other cardiovascular therapies New Rx Total Rx 80% 100% 92% 70% 70% 89% 90% 90% 70% 63% 80% Percentage growth Percentage growth 60% 70% 50% 60% 40% 50% 40% 30% 30% 24% 20% 21% 21% 20% 10% 9% 10% 6% 5% 10% 3% 5% 3% 4% 2% 0% 0% Month Quarter MAT Month Quarter MAT Vascepa PCSK
Slide 6: Broadening the user base
Vascepa: Broadening the user base Total Rx by Physician Group 2500 2000 As market access increases, General Practitioner our strategy is to leverage the 4x expansion in physician 1500 Cardiologist Endocrinologist audience to 10,000 with 1000 IM greater call frequency to 500 Other create awareness, t
Slide 7: Catalysts in place to drive Vascepa growth
Vascepa: Catalysts in place to drive Vascepa growth Public payer coverage Private payer coverage ~70% publicly covered lives eligible for Vascepa >95% privately covered lives eligible for Vascepa reimbursement, including: reimbursement Ontario, Quebec, Saskatchewan, New Brunswick and Northwest Terri
Slide 8: 2023 net revenue outlook
Vascepa: 2023 net revenue outlook 2022 2023 (forecast) Vascepa net revenue: Vascepa net revenue outlook: C$12.3mm C$22-28mm Q1’23 Vascepa net sales expected to be 40-50% higher than Q1’22, in Canadian dollars Provided as part of an oral presentation and qualified by such, contains forward-looking st
Slide 9: Q4 & F2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q4 & F2022 Results Conference Call March 16, 2023 TSX - HLS